Most Oral Peptides Don't Work

Why It Matters

Ineffective oral peptides limit market growth and compel innovation in delivery methods, impacting investors, manufacturers, and patients seeking non‑injectable therapies.

Key Takeaways

• Most oral peptides are ineffective due to molecular size
• Insulin exemplifies why large peptides require injection for treatment
• Only small peptides can survive gastrointestinal digestion orally
• Injectable delivery remains the reliable method for peptide efficacy
• Choose oral peptides selectively if they’re proven absorbable

Summary

The video asserts that oral administration of most peptide therapeutics fails, highlighting a fundamental limitation in the market.

It explains that peptide size, exemplified by insulin's 52‑amino‑acid chain, leads to enzymatic degradation in the gastrointestinal tract, making injection necessary; only peptides small enough can be absorbed.

The speaker notes, "If they could do an insulin pill, every diabetic would be taking it," underscoring the demand for oral options, and advises consumers to select only those peptides with proven oral bioavailability.

This reality constrains supplement vendors, pushes developers toward advanced delivery technologies, and signals investors to scrutinize oral peptide claims.

Original Description

Nutritionist, naturopath, and peptide formulator Kyal Van Der Leest breaks down the peptides that actually matter for midlife women — from BPC-157 (the Swiss Army knife of peptides) to GHK-Copper for skin-from-within glow-ups, to the real talk on GLP-1s that nobody's having.

Watch the full episode at https://youtu.be/XFte5B2VzWI